Special Issue "The Emerging Hallmarks of Cancer Metabolism for Precision Oncology Applications"
Deadline for manuscript submissions: 1 October 2021.
Interests: biomarkers for the individualized radiotherapy; metabolic biomarkers for cancers; cancer stem cells; molecular mechanisms of cancer radioresistance; therapy-induced tumor reprogramming; tumor radiosensitization
Interests: intrinsic and microenvironment-mediated radiation resistance; cell and tissue responses to ionizing radiation; stress-induced metabolic reprogramming; biomarkers for radiosensitivity; combinatorial treatments for tumor radiosensitization and normal tissue protection
Special Issues and Collections in MDPI journals
Interests: tumor pathophysiology; tumor micromilieu and cellular environment; tumor cell metabolism; metabolic targeting and co-targeting; 3-D assays; photon and proton therapy
The ultimate goal of precision oncology is a more tailored and individualized treatment for cancer patients. However, reliable predictive biomarkers of therapy response along with effective treatments with low toxicity are still rare for many types of tumors. Thus, new strategies for personalized medicine including biomarkers for patient stratification, as well as novel targets for combinatorial treatment regimes need to be developed for improving the prognosis of cancer patients suffering from common cancer types with high rates of local recurrence or metastasis. Reprogramming of cellular metabolism is one of the major hallmarks of cancer cells that plays an important role in tumor initiation and progression, as well as in therapy resistance and tumor immune escape. Thus, biochemical and molecular metabolic features of tumors might serve as specific biomarkers for identifying patients who will most likely benefit from a given therapy. Furthermore, targeting tumor metabolism emerged as a novel, highly potent avenue to enhance the efficacy of conventional anti-cancer treatments such as radio- and chemotherapy as well as immunotherapy approaches. This Special Issue is aimed at summarizing the emerging hallmarks of cancer metabolism across major tumor types and the prospects for clinical development of anti-metabolic therapy and reliable biomarkers to optimize treatment decisions.
Prof. Dr. Anna Dubrovska
Prof. Dr. Verena Jendrossek
Prof. Dr. Leoni Kunz-Schughart
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- metabolic reprogramming
- metabolic immune-adaptations
- metabolic co-targeting
- metabolic biomarkers